Impel Pharmaceuticals Inc. (IMPL) Misses Q2 EPS by 4c

Impel Pharmaceuticals Inc. (NASDAQ: IMPL) reported Q2 EPS of ($1.09), $0.04 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.84 million.

For earnings history and earnings-related data on Impel Pharmaceuticals Inc. (IMPL) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery